drugset / Trial / NCT02856919

A Multicenter, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Once Daily Mirvaso® Gel in Patients With Chronic Persistent Vascular Facial Erythema.

NCT02856919

NaSingle-groupOpen-labelTreatment

Summary

This study evaluates the efficacy of Mirvaso® in the treatment of chronic persistent vascular facial erythema, after 4 weeks of treatment, by the Clinician erythema assessment.

Timeline

Start
2016-06-13
Primary completion
2017-02-08
Completion
2017-02-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Brimonidine Small molecule 5 unknown Topical

Indications

No indication recorded.